G01N 2333/57
Ifn-gamma
Official title: IFN-gamma
G01N2333/57 (Ifn-gamma) appears on 163 US grants and 366 published applications in this corpus.
Search patents in G01N- Granted patents
- 163
- Published applications
- 366
- Assignees
- 252
- Inventors
- 783
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 9 |
| 2004 | 0 | 2 |
| 2005 | 1 | 5 |
| 2006 | 1 | 1 |
| 2007 | 1 | 5 |
| 2008 | 2 | 10 |
| 2009 | 3 | 6 |
| 2010 | 4 | 11 |
| 2011 | 5 | 6 |
| 2012 | 4 | 12 |
| 2013 | 3 | 11 |
| 2014 | 5 | 8 |
| 2015 | 10 | 27 |
| 2016 | 14 | 35 |
| 2017 | 15 | 34 |
| 2018 | 17 | 22 |
| 2019 | 13 | 20 |
| 2020 | 10 | 24 |
| 2021 | 11 | 23 |
| 2022 | 8 | 27 |
| 2023 | 8 | 7 |
| 2024 | 10 | 29 |
| 2025 | 9 | 18 |
| 2026 | 7 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Genetically modified mice having a humanized programmed cell death 1 gene14 Jul 2026US 12,677,813 B2Regeneron Pharmaceuticals, Inc.
- Methods of treating an autoimmune disease with a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3)14 Jul 2026US 12,678,485 B2Stemline Therapeautics, Inc.
- Diagnostic blood test for sarcoidosis21 Apr 2026US 12,607,639 B2
- Methods and compositions for T-cell coculture potency assays and use with cell therapy products10 Mar 2026US 12,570,961 B2Iovance Biotherapeutics, Inc.
- Method for diagnosing and treating fibromyalgia24 Feb 2026US 12,560,614 B2Center for Immunology Science
- Biomarkers for predicting cancer treatment efficacy10 Sep 2026US 2026/0266828 A1Arcus Biosciences, Inc.
- Humoral Immune Activators for the Treatment of Humoral Immunosuppressed Pathologies, Cancer and Infectious Disease and Humoral Immune Suppressors for the Treatment of Inflammatory Diseases3 Sep 2026US 2026/0256811 A1Navrogen, Inc.
- Affinity and functional based screening of t cell receptor repertoire using three-dimensional shaped particles30 Jul 2026US 2026/0218282 A1The Regents of the University of California
- Methods of predicting and treating immunotherapy adverse events based on immune cell populations16 Jul 2026US 2026/0202406 A1Board of Regents, The University of Texas System
- Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex16 Jul 2026US 2026/0204354 A1Adaptimmune Limited
Most cited
By later US patents
- Methods and apparatus for conducting multiple measurements on a sample125US 7,858,321 B2Meso Scale Technologies, LLC. · 2010
- Method for treating malignant melanoma38US 8,211,424 B2SentoClone International AB · 2012
- Process for the measurement of the potency of glatiramer acetate30US 7,429,374 B2Teva Pharmaceutical Industries Ltd. · 2008
- Process for the measurement of the potency of glatiramer acetate28US 7,923,215 B2Teva Pharmaceutical Industries Ltd. · 2011
- Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate20US 8,709,433 B2Teva Pharmaceutical Industries Ltd. · 2014